Galectin <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Reports Positive Phase 2 NAVIGATE Trial Results for Belapectin in MASH Cirrhosis
Galectin Therapeutics Inc. announced new results from the Phase 2b NAVIGATE trial evaluating belapectin, a galectin-3 inhibitor, in patients with compensated MASH cirrhosis and portal hypertension. The data were presented at the American Association for the Study of Liver Diseases (AASLD) 2025 Annual Meeting. In the 18-month, randomized, double-blind, placebo-controlled trial involving 355 patients, belapectin 2 mg/kg demonstrated consistent antifibrotic effects, including sustained improvements in liver stiffness and reductions in multiple serum biomarkers such as ELF, PRO-C3, and YKL-40. The rate of adverse events and serious adverse events was comparable to placebo, with no drug-related serious adverse events reported. Additionally, a lower proportion of patients treated with belapectin 2 mg/kg experienced clinically significant increases in liver stiffness compared to placebo, and the treatment was associated with a sustained reduction in new variceal development for patients completing 36 months of therapy.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galectin Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-25-041275), on November 10, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.